Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080352746> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2080352746 endingPage "66" @default.
- W2080352746 startingPage "60" @default.
- W2080352746 abstract "The present studies were designed to examine whether treatment of disseminated melanoma with a combination of recombinant interferon alpha (rIFN alpha-2a) and DTIC may provide better results than either agent alone. Two dose levels of rIFN alpha-2a were examined with the same dose and schedule of DTIC administration. In the first study 76 patients were treated with rIFN alpha-2a (3 x 10(6) IU days 1-3, 9 x 10(6) IU days 4-70 then 9 x 10(6) IU TIW) plus DTIC (i.v. 200 mg/m2, escalating to 800 mg/m2 each 21 d) for 6 months or longer or until failure. Responses were seen in 26% of patients overall (7CR, 13PR) with the highest responses being seen in those assessed as having a good prognosis and in patients with skin and/or lung metastases. It was notable that males showed a better response than females and that patients with metastases in lymph nodes showed low responses. Response rates in 30 patients treated with high-dose rIFN alpha-2a (18 x 10(6) IU days 7-70) were not superior to that seen at the lower dose and was accompanied by significant increase in bone marrow toxicity. The duration of responses appeared longer than expected from responses to DTIC alone and four patients remain progression free at periods in excess of 3 years. Failure in nine of the responders was due to the development of brain metastases which emphasizes the need for additional treatment approaches to treat micrometastases at this site. The results of a randomized control study comparing DTIC alone with DTIC plus 'low' dose rIFN alpha-2a are awaited with interest." @default.
- W2080352746 created "2016-06-24" @default.
- W2080352746 creator A5023400770 @default.
- W2080352746 creator A5053260042 @default.
- W2080352746 creator A5055038393 @default.
- W2080352746 date "1991-10-01" @default.
- W2080352746 modified "2023-09-24" @default.
- W2080352746 title "Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies" @default.
- W2080352746 cites W184247245 @default.
- W2080352746 cites W1967658581 @default.
- W2080352746 cites W1973089244 @default.
- W2080352746 cites W1985366163 @default.
- W2080352746 cites W1985560312 @default.
- W2080352746 cites W2009041500 @default.
- W2080352746 cites W2051368411 @default.
- W2080352746 cites W2078045193 @default.
- W2080352746 cites W2078530112 @default.
- W2080352746 cites W2092690255 @default.
- W2080352746 cites W2110489989 @default.
- W2080352746 cites W2167805334 @default.
- W2080352746 doi "https://doi.org/10.1111/j.1365-2141.1991.tb08122.x" @default.
- W2080352746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1931712" @default.
- W2080352746 hasPublicationYear "1991" @default.
- W2080352746 type Work @default.
- W2080352746 sameAs 2080352746 @default.
- W2080352746 citedByCount "17" @default.
- W2080352746 countsByYear W20803527462012 @default.
- W2080352746 countsByYear W20803527462015 @default.
- W2080352746 crossrefType "journal-article" @default.
- W2080352746 hasAuthorship W2080352746A5023400770 @default.
- W2080352746 hasAuthorship W2080352746A5053260042 @default.
- W2080352746 hasAuthorship W2080352746A5055038393 @default.
- W2080352746 hasConcept C121608353 @default.
- W2080352746 hasConcept C126322002 @default.
- W2080352746 hasConcept C141071460 @default.
- W2080352746 hasConcept C203014093 @default.
- W2080352746 hasConcept C2776178377 @default.
- W2080352746 hasConcept C2776694085 @default.
- W2080352746 hasConcept C2777658100 @default.
- W2080352746 hasConcept C2777701055 @default.
- W2080352746 hasConcept C2780964509 @default.
- W2080352746 hasConcept C2781228144 @default.
- W2080352746 hasConcept C2909179924 @default.
- W2080352746 hasConcept C29730261 @default.
- W2080352746 hasConcept C502942594 @default.
- W2080352746 hasConcept C71924100 @default.
- W2080352746 hasConcept C90924648 @default.
- W2080352746 hasConceptScore W2080352746C121608353 @default.
- W2080352746 hasConceptScore W2080352746C126322002 @default.
- W2080352746 hasConceptScore W2080352746C141071460 @default.
- W2080352746 hasConceptScore W2080352746C203014093 @default.
- W2080352746 hasConceptScore W2080352746C2776178377 @default.
- W2080352746 hasConceptScore W2080352746C2776694085 @default.
- W2080352746 hasConceptScore W2080352746C2777658100 @default.
- W2080352746 hasConceptScore W2080352746C2777701055 @default.
- W2080352746 hasConceptScore W2080352746C2780964509 @default.
- W2080352746 hasConceptScore W2080352746C2781228144 @default.
- W2080352746 hasConceptScore W2080352746C2909179924 @default.
- W2080352746 hasConceptScore W2080352746C29730261 @default.
- W2080352746 hasConceptScore W2080352746C502942594 @default.
- W2080352746 hasConceptScore W2080352746C71924100 @default.
- W2080352746 hasConceptScore W2080352746C90924648 @default.
- W2080352746 hasIssue "s1" @default.
- W2080352746 hasLocation W20803527461 @default.
- W2080352746 hasLocation W20803527462 @default.
- W2080352746 hasOpenAccess W2080352746 @default.
- W2080352746 hasPrimaryLocation W20803527461 @default.
- W2080352746 hasRelatedWork W1212782987 @default.
- W2080352746 hasRelatedWork W2356441863 @default.
- W2080352746 hasRelatedWork W2394601029 @default.
- W2080352746 hasRelatedWork W2397644467 @default.
- W2080352746 hasRelatedWork W2399690102 @default.
- W2080352746 hasRelatedWork W2409032034 @default.
- W2080352746 hasRelatedWork W2419299658 @default.
- W2080352746 hasRelatedWork W4301173793 @default.
- W2080352746 hasRelatedWork W775998430 @default.
- W2080352746 hasRelatedWork W99073025 @default.
- W2080352746 hasVolume "79" @default.
- W2080352746 isParatext "false" @default.
- W2080352746 isRetracted "false" @default.
- W2080352746 magId "2080352746" @default.
- W2080352746 workType "article" @default.